Document is current

Any future updates will be listed below

Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

Crossref DOI link: https://doi.org/10.1007/s00280-016-2993-y

Published Online: 2016-03-03

Published Print: 2016-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark